Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Differential profile of PIP4K2A expression in hematological malignancies

Full text
Author(s):
Lima, Keli [1] ; Ribeiro, Daniela Maria [1] ; Campos, Paula de Melo [2] ; Costa, Fernando Ferreira [2] ; Traina, Fabiola [2] ; Olalla Saad, Sara Teresinha [2] ; Sonati, Maria de Fatima [1] ; Machado-Neto, Joao Agostinho
Total Authors: 8
Affiliation:
[1] Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Pathol, Sao Paulo - Brazil
[2] Univ Campinas UNICAMP, Hematol & Hemotherapy Ctr, Inst Natl Ciencia & Tecnol Sangue, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: BLOOD CELLS MOLECULES AND DISEASES; v. 55, n. 3, p. 228-235, OCT 2015.
Web of Science Citations: 2
Abstract

PIP4K2A is a lipid kinase that phosphorylates PtdIns5P, generating PtdIns4,5P(2). Recently, PIP4K2A was identified as a potential target in acute myeloid leukemia cells. The objective of the present study was to investigate the PIP4K2A expression in hematological malignancies and verify the effects of PIP4K2A silencing on proliferation and survival of leukemia cell lines. PIP4K2A was found to be a cytoplasmic and nuclear protein with reduced levels in leukemia cell lines compared to normal leukocytes. PIP4K2A mRNA levels were significantly reduced in bone marrow cells from acute lymphoid leukemia (ALL) patients compared with healthy donors and in myelodysplastic syndromes (MDS) with >= 5% compared with <5% bone marrow blasts. Low PIP4K2A expression (lowest tertile versus 2 higher tertiles) negatively impacted overall survival of MDS patients by univariate analysis. PIP4K2A silencing did not modulate cell proliferation, clonogenicity and apoptosis of HEL and Namalwa leukemia cells. In summary, we characterized the expression of PIP4K2A in a cohort of patients with hematological malignancies and we found that PIP4K2A mRNA expression is downregulated in RAEB-1/RAEB-2 MDS and ALL cells, and PIP4K2A silencing does not modulate cell survival in HEL and Namalwa leukemia cells. (C) 2015 Elsevier Inc All rights reserved. (AU)

FAPESP's process: 11/51959-0 - Biology of neoplastic diseases of bone marrow
Grantee:Sara Teresinha Olalla Saad
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 14/00984-3 - Red blood cell disorders: pathophysiology and new therapeutic approaches
Grantee:Fernando Ferreira Costa
Support Opportunities: Research Projects - Thematic Grants